Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 1.00 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL29387447 | 1.00 | — | — | |
| Cysteine SCHEMBL7898895 | 1.00 | PTGS1 (1.00) | PTGS1SLC7A11ENPEPSLC1A1SLC1A3 | |
| Cysteine SCHEMBL29965523 | 1.00 | — | — | |
| Cysteine SCHEMBL95110 | 1.00 | — | — | |
| Cysteine SCHEMBL5705426 | 1.00 | PTGS1 (1.00) | PTGS1SLC7A11ENPEPSLC1A1SLC1A3 | |
| Cysteine SCHEMBL5705430 | 1.00 | PTGS1 (1.00) | PTGS1SLC7A11ENPEPSLC1A1SLC1A3 | |
| Cysteine SCHEMBL1868335 | 1.00 | PTGS1 (1.00) | PTGS1SLC7A11ENPEPSLC1A1SLC1A3 | |
| Cysteine SCHEMBL4289403 | 1.00 | — | — | |
| Cysteine SCHEMBL21110883 | 1.00 | PTGS1 (1.00) | PTGS1SLC7A11ENPEPSLC1A1SLC1A3 | |
| Cysteine SCHEMBL30607088 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107488576-A | A kind of preparation method for the micro-fluidic chip for embedding oriented nanofibers film | 东华大学 | 2017-12-19 | — | — | CN | claimed |
| US-9005926-B2 | Methods of preventing and removing trisulfide bonds | BIOGEN IDEC MA INC. (US) | 2015-04-14 | — | — | US | claimed |
| US-8501679-B2 | Cyclic, cystein-free protein | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2013-08-06 | — | — | US | claimed |
| EP-2217619-B1 | CYCLIC, CYSTEIN-FREE PROTEIN | APEPTICO FORSCHUNG & ENTWICKLUNG GMBH (AT) | 2012-11-07 | — | — | EP | claimed |
| WO-2010146142-A9 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2011-06-16 | — | — | WO | claimed |
| US-20110105414-A1 | CYCLIC, CYSTEIN-FREE PROTEIN | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2011-05-05 | — | — | US | claimed |
| US-20100016550-A1 | Methods for Site-Specific Pegylation | IPSEN PHARMA S.A.S. (FR) | 2010-01-21 | — | — | US | claimed |
| US-20050221453-A1 | L-cysteine producing microorganism and method for producing L-cysteine | AJINOMOTO CO., INC (JP) | 2005-10-06 | — | — | US | claimed |
| US-20240041919-A1 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION | GALLEON LABS LLC | 2024-02-08 | — | — | US | disclosed |
| WO-2023222854-A1 | USES OF ANTI-ICOS ANTIBODIES | KYMAB LIMITED (GB) | 2023-11-23 | — | — | WO | disclosed |
| US-11801261-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | GALLEON LABS LLC (US) | 2023-10-31 | — | — | US | disclosed |
| EP-3507300-B1 | WOUND HEALING PEPTIDE | UNIV JAMES COOK (AU) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022179536-A1 | FERRITIN HEAVY CHAIN SUBUNIT MUTANT AND APPLICATION THEREOF | 昆山新蕴达生物科技有限公司 | 2022-09-01 | — | — | WO | disclosed |
| WO-2022169344-A1 | NEWCASTLE DISEASE VIRUS WITH IMPROVED HEAT RESISTANCE, AND NEWCASTLE DISEASE VIRUS VACCINE COMPRISING SAME | 주식회사 바이오포아 | 2022-08-11 | — | — | WO | disclosed |
| WO-1994009128-A1 | THERAPEUTIC TREATMENT FOR INHIBITING VASCULAR RESTENOSIS | MALLINCKRODT MEDICAL, INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| US-4956467-A | CLEAVAGE OF PROTEINS AND SEQUENCE DETERMINATION | AMERICAN CYANAMID COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0339217-A2 | Specific peptide bond cleavage by organic tertiary phosphines with nucleophilic side chains | CARTER-WALLACE, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| US-4524014-A | Photobleach system, composition and process | LEVER BROTHERS COMPANY (US) | 1985-06-18 | — | — | US | disclosed |
| US-4272517-A | N-CARBAMOYLCYSTEINE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-06-09 | — | — | US | disclosed |
| US-4012576-A | AMINOGLYCOSIDE ANTIBIOTIC | BRISTOL-MYERS COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016550-A1 | Methods for Site-Specific Pegylation | CTH, CBS, SELENOI | PTGS1 1979/4885SLC7A11 18/4885ENPEP 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.